Skip to content

Drug interactions

Ivosidenib + Pazopanib

Severity: Major

Ivosidenib and Pazopanib: major interaction.

Last updated Sources: US FDA label

For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.

Summary

Both drugs can prolong the QTc interval, raising the risk of arrhythmia. Ivosidenib also induces CYP3A4 and may lower pazopanib exposure, potentially reducing its efficacy.

What this interaction means in plain words

Ivosidenib and Pazopanib can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.

Ivosidenib belongs to Oncology; Pazopanib belongs to Oncology.

Evidence level: Moderate

Why it happens

Additive QT prolongation plus CYP3A4 induction by ivosidenib that increases pazopanib clearance.

What to do

Avoid the combination if possible. If unavoidable, monitor ECG and electrolytes and watch for reduced pazopanib effect.

What to ask your pharmacist

  • Does the benefit of taking both outweigh the risk in my case?
  • Do I need any blood test, ECG or other check while on both?
  • What early warning signs should I watch for, and what should I do if they appear?

Bring a full list of your medicines, including over-the-counter products, supplements and herbal remedies, to every pharmacy visit.

Pro+ members

Unlock the full page

Create an account and start a Pro+ trial to unlock the full management advice for Ivosidenib and Pazopanib, the additional notes, the evidence detail and the whole-prescription interaction checker.

  • Full clinical management advice
  • Additional notes
  • Evidence detail
  • Interaction checker for a whole prescription

Try Pro+ free for 7 days on the web. No card needed.

References

Frequently asked questions

Can I take Ivosidenib with Pazopanib?

MediHelp rates the interaction as major. Ivosidenib and Pazopanib can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Both drugs can prolong the QTc interval, raising the risk of arrhythmia. Ivosidenib also induces CYP3A4 and may lower pazopanib exposure, potentially reducing its efficacy.

How serious is the interaction between Ivosidenib and Pazopanib?

MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid the combination if possible. If unavoidable, monitor ECG and electrolytes and watch for reduced pazopanib effect.

What other medicines interact with Pazopanib?

MediHelp also lists interactions of Pazopanib with, for example, Adagrasib, Amiodarone, Amisulpride. The full list is on the Pazopanib page.

Full monographs, dosing and an interaction checker in the MediHelp app

Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.

Browse A–Z · Drug interactions

Get the app Sign in